Akshat Jain: NEJM Group Study Demonstrates Platelet Responses in ITP Treated with Mezagitamab
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn about a recent article by David J. Kuter et al. published in NEJM, adding:
“Exciting new data in ITP treatment : a phase 2 NEJM Group study found that mezagitamab, a CD38-targeting antibody, produced rapid and sustained platelet responses, with the highest dose showing a platelet response in 91% of patients by week 16 and a safety profile similar to placebo.
Why this matters: ITP remains an area of major unmet need, and this therapy may represent a true shift from symptom control toward disease modification by targeting the immune cells driving platelet destruction.
If confirmed in phase 3, mezagitamab could meaningfully change the treatment landscape for patients who do not respond well to current options.
600 mg dose achieving a platelet response in 91% of patients by week 16 and a tolerability profile comparable to placebo.
This is especially important in ITP, where many patients still have limited durable responses to existing therapies.
By targeting CD38-expressing immune cells, mezagitamab may offer a more disease-modifying approach rather than just temporary platelet support.”
Title: A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
Authors: David J. Kuter, Katsuhiro Miura, Andrea Patriarca, Dražen Pulanić, Atanas Radinoff, Katya Sapunarova, Antonia Syrigou, Renchi Yang, Van Anh Nguyen, Emily Skelton, Scarlett Wang, Donald L. Yee, Parth Patwari
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 26, 2026, 13:48Jecko Thachil։ How to Anticoagulate Patients with Thrombocytopenia and Thrombosis
-
Apr 26, 2026, 13:41Ayesha Saleem: Bridging the Gap Between Awareness and Diagnosis of vWD in Pakistan
-
Apr 26, 2026, 13:20Tasawar Siddique: Early Detection of Nephrotic Syndrome
-
Apr 26, 2026, 12:51Michael Stark: Join the Discussion on Cord Blood vs Adult Blood
-
Apr 26, 2026, 12:21Alex John London: AI in Healthcare Must Show Safety and Efficacy Before Use
-
Apr 26, 2026, 12:01David McIntosh: Raising Awareness on the Worldwide Shortage of Plasma-Derived Medicines
-
Apr 26, 2026, 12:00José Antonio García Erce: Where Is the Limit in Blood Donation Age?
-
Apr 26, 2026, 11:59Tomas Holubec: A New Chapter in Cardiac Surgery in Nuremberg
-
Apr 26, 2026, 11:58Emna Hammami: Great First Session at the EHA SWG Scientific Meeting on Bleeding and Platelet Disorders